Finepoint Capital LP
- SEC CIK
- 0001608126
- Latest filing
- Aug 13, 2026
Holdings in Q2 2025
Holdings as of Jun 30, 2025, filed Aug 13, 2025. Long positions only; changes compare share counts with Q1 2025.
- Positions
- 8
- −15 vs. Q1 2025
- Portfolio value
- $504.3M
- −$88.5M (−14.9%) vs. Q1 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| QXOQXO, Inc. | COM NEW | 21,152,868 | $455.6M | 90.4% | −3,315,292−13.5% | Reduced | History |
| LLYVKLiberty Live Holdings, Inc. | COM LBTY LIV S C | 537,051 | $43.6M | 8.6% | +104,156+24.1% | Added | History |
| SLDBSolid Biosciences Inc. | COM NEW | 961,251 | $4.68M | 0.9% | 00.0% | Unchanged | History |
| ANNAAleAnna, Inc. | COM CL A | 27,717 | $199.6K | <0.1% | 00.0% | Unchanged | History |
| ANNAWAleAnna, Inc. | *W EXP 12/13/202 | 490,000 | $115.2K | <0.1% | 00.0% | Unchanged | History |
| MNYWWMoneyHero Ltd | *W EXP 09/13/202 | 895,000 | $41.9K | <0.1% | 00.0% | Unchanged | History |
| Ys Biopharma Co LtdG9845F117 | *W EXP 03/15/202 | 489,999 | $19.6K | <0.1% | 00.0% | Unchanged | – |
| CLDICalidi Biotherapeutics, Inc. | COM | 12,499 | $2.88K | <0.1% | 00.0% | Unchanged | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| SPYSPDR S&P 500 ETF Trust | ETF | $725.0M | – |
| iShares Russell 2000 ETF464287655 | ETF | $126.2M | – |
Sold out since Q1 2025 (15)
Positions held at the end of Q1 2025 that are gone from this filing.
| Security | Class | Shares in Q1 2025 | Value in Q1 2025 | % of portfolio in Q1 2025 | History |
|---|---|---|---|---|---|
| LBRDKLiberty Broadband Corp | COM SER C | 529,240 | $45.0M | 7.6% | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 728,602 | $32.2M | 5.4% | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 179,872 | $28.0M | 4.7% | History |
| RVMDRevolution Medicines, Inc. | COM | 691,260 | $24.4M | 4.1% | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 435,785 | $17.0M | 2.9% | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 656,587 | $16.5M | 2.8% | History |
| CYTKCytokinetics Inc | COM NEW | 309,948 | $12.5M | 2.1% | History |
| Avidity Biosciences, Inc.05370A108 | COM | 380,700 | $11.2M | 1.9% | – |
| SRPTSarepta Therapeutics, Inc. | COM | 157,555 | $10.1M | 1.7% | History |
| PRTAProthena Corp Public Ltd Co | SHS | 640,071 | $7.92M | 1.3% | History |
| XNCRXencor Inc | COM | 642,200 | $6.83M | 1.2% | History |
| EYPTEyePoint, Inc. | COM NEW | 1,081,954 | $5.86M | 1.0% | History |
| RLAYRelay Therapeutics, Inc. | COM | 2,117,646 | $5.55M | 0.9% | History |
| ARVNArvinas, Inc. | COM | 694,028 | $4.87M | 0.8% | History |
| Marblegate Acquisition Corp.56608A113 | *W EXP 08/31/202 | 735,000 | $117.6K | <0.1% | – |